📅 PUBMED DAILY TRIAGE — 2026-05-05

Window: 2026-05-04T09:00:00Z → 2026-05-05T09:00:00Z (CRDT) Topics scanned: 10 | Candidates evaluated: ~80 | Articles kept: 23 High priority: 4 | Standard: 19 | Low/archive: ~15 | Unsolicited finds: 2 Run status: ✅ SUCCESS

🔴🟠 HIGH PRIORITY (≥8 or NOVEL_TREATMENT/EARLY_CANCER_DETECTION flag)

Hematologic Malignancies + Novel Therapeutics

TR-2026-05-05-001 · PMID 42082682 · Score 9/10 · 🟠 NOVEL_TREATMENT Rosuvastatin enhances venetoclax-azacitidine in older AML via T-cell exhaustion reduction (Cancer Immunol Immunother, May 2026) Multicenter Phase II trial: triple combination (rosuvastatin + ven-aza) achieved CRc 72.2% with deep MRD negativity in 84.6% of responders and significantly reduced PD-1⁺ T-cell exhaustion (p≈0.013–0.028). Median OS 18 months, RFS 14 months at 10-month follow-up. ← Novel statin-mediated immune rescue mechanism in an older/unfit AML population with high unmet need.

AI/ML in Clinical Diagnostics

TR-2026-05-05-002 · PMID 42082713 · Score 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE Digepath: subspecialty-specific foundation model for intelligent GI pathology (npj Digital Medicine, May 2026) SOTA on 32/33 GI pathology downstream tasks (diagnosis, molecular profiling, survival) after pretraining on 353M patches from 210,043 H&E slides + fine-tuning on 471K expert-annotated regions. Includes clinical reasoning agent for end-to-end deployment. ← Ready-to-deploy AI pathology for GI cancers.

Rare Diseases

TR-2026-05-05-003 · PMID 42078615 · Score 7/10 · 🟠 NOVEL_TREATMENT Vykat XR (diazoxide choline-ER): first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome (Ann Med Surg, Apr 2026) FDA approved March 27, 2025 for ages ≥4 years — first-ever pharmacologic therapy for hyperphagia in PWS. Decades-long unmet need; hyperphagia-driven obesity is the primary cause of PWS morbidity and mortality. ← Milestone regulatory event for an ultra-rare disease.

Sentinel / Unsolicited Find

TR-2026-05-05-004 · PMID 42082916 · Score 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE (unsolicited find) Saliva PCR vs DBS PCR for congenital CMV detection: systematic review + meta-analysis (BMC Infect Dis, May 2026) 19 studies, 103,669 neonates: saliva PCR pooled sensitivity 95% vs DBS PCR 72% (p=0.004); specificities near-identical (≥99%). SROC AUC 0.72 vs 0.56. cCMV = #1 non-genetic cause of congenital hearing loss. ← Definitive evidence for saliva PCR as preferred newborn cCMV screening modality.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies (best score 7; 1 HIGH, 3 STANDARD)

• TR-2026-05-05-005 · PMID 42082719 · 7/10 · Genomics/Precision Medicine Transposable elements shape stemness in AML leukemia stem cells (Nature Genetics, May 2026) — 121 TE subfamilies stratify AML patients by stemness/survival; LTR12C elements maintain LSC identity via LYL1; chromatin editing confirms causal role. Major mechanistic advance for AML relapse biology.
• TR-2026-05-05-006 · PMID 42083006 · 6/10 · Diagnostics MTX nephrotoxicity PKPD model in PCNSL (Clin Pharmacol Ther, May 2026) — 5,918 samples from 743 patients; nephrotoxicity thresholds at 24/48/72h; hemoglobin as strongest covariate predictor.
• TR-2026-05-05-007 · PMID 42082740 · 5/10 · Public Health Psychological distress in indolent NHL (Supp Care Cancer, May 2026) — 30.7% of 352 iNHL patients distressed; distress strongest QoL predictor (β=−0.605); watchful waiting patients most at risk.

CBC/ML Hematology: No high-priority finds (13th consecutive run). Best score 5/10.

Early Cancer Detection (best score 7; 0 HIGH, 5 STANDARD)

• TR-2026-05-05-008 · PMID 42082165 · 7/10 · Diagnostics / EARLY_CANCER_DETECTION ctDNA monitoring in uveal melanoma via mutation-agnostic multiplex drop-off ddPCR (Anal Chem, May 2026) — Detection limits 0.06–0.13%, concordance r=0.97–0.98 with simplex ddPCR; eliminates need for prior tumor NGS genotyping. Institut Curie, prospective ALCINA cohort.
• TR-2026-05-05-009 · PMID 42082368 · 6/10 · Early Detection ctDNA for CRC MRD and adjuvant therapy individualization (Klin Onkol, 2026) — Synthesis of DYNAMIC, GALAXY, BESPOKE CRC; ctDNA-guided de-escalation non-inferior to standard therapy; ongoing trials testing escalation.
• TR-2026-05-05-010 · PMID 42082962 · 5/10 · Public Health / UNDERSERVED_POPULATION Cervical cancer screening barriers in Uganda (BMC Health Serv Res, May 2026) — Multi-level barriers (fear, stigma, partner opposition, distance) despite free VIA screening; decentralization + sensitization are key facilitators.
• TR-2026-05-05-011 · PMID 42082236 · 5/10 · Early Detection LUCIA lung cancer risk study protocol (BMJ Open, May 2026) — n=4,000, 4 European countries; AI + breath analyzer + VOC patches for never-smoker lung cancer risk. NCT06473870.

AI/ML in Clinical Diagnostics (best score 8; 1 HIGH, 3 STANDARD)

• TR-2026-05-05-012 · PMID 42083001 · 5/10 · Genomics/Precision Medicine AI-driven genomic + exposome cancer risk (CRS) (Hum Genomics, May 2026) — Review: PRS/CRS consistently stratify relative risk but AUC gains modest; recommended for screening enrichment not clinical decision support.
• TR-2026-05-05-013 · PMID 42082707 · 6/10 · Diagnostics AI TIL spatial analysis identifies prognostic immune niches in CRC (Cancer Immunol Immunother, May 2026) — TSB score from H&E achieves Immunoscore-equivalent RFS prognosis (n=202, stage II–III CRC) without IHC.

Precision Oncology / Genomic Medicine (best score 6; 0 HIGH, 3 STANDARD)

• TR-2026-05-05-022 · PMID 42079859 · 5/10 · Drug Development FDA 2025 cancer drug approvals (Explor Target Antitumor Ther, Apr 2026) — Cancer 35% of all approvals; kinase inhibitors ~half; CDx co-approval gap identified as systemic precision medicine access barrier.

Novel Therapeutics (best score 9 via TR-001; 0 additional HIGH, 2 STANDARD via overlap)

See TR-2026-05-05-001 (AML rosuvastatin, score 9) — primary find for this topic.

Cardiovascular-Metabolic (best score 7; 0 HIGH, 4 STANDARD)

• TR-2026-05-05-014 · PMID 42082865 · 7/10 · Prevention Tirzepatide shifts WHtR risk categories in SURMOUNT-1 post-hoc (J Endocrinol Invest, May 2026) — 54.7% improved WHtR category at 72 weeks vs 9.6% placebo; 16.7% reached lowest-risk WHtR (≤0.49); sustained at 176 weeks. [Lilly-funded]
• TR-2026-05-05-015 · PMID 42082683 · 6/10 · Diagnostics Pulse pressure predicts CV outcomes in stable CAD (npj Cardiovasc Health, May 2026) — Prospective N=7,027; PP independent predictor of stroke (HR 1.019) and combined events; superior to SBP as predictor.
• TR-2026-05-05-016 · PMID 42082380 · 5/10 · Prevention / UNDERSERVED_POPULATION CVD risk control reduces atherosclerosis progression in multiethnic lupus cohort (Lupus Sci Med, May 2026) — N=69, 40% non-Caucasian, 63-month follow-up; anti-La positivity unexpectedly protective (novel finding).
• TR-2026-05-05-018 · PMID 42082375 · 5/10 · Diagnostics LV thrombus: Takotsubo vs STEMI (Open Heart, May 2026) — 0% LV thrombus in Takotsubo despite worse LV function vs 8.1% in anterior STEMI; challenges blanket anticoagulation in Takotsubo.

Aging, Longevity, Population Health (best score 7; 0 HIGH, 3 STANDARD)

• TR-2026-05-05-017 · PMID 42082383 · 7/10 · Prevention / UNDERSERVED_POPULATION BHARAT study: first large-scale multi-omics aging cohort for India (Aging, Apr 2026) — IISc-led, hub-and-spoke, multi-omics (epigenomics, proteomics, metabolomics, lipidomics, metagenomics) across 5 age groups; targets Indian-specific biological clock calibration for 347M projected elderly by 2050.

Rare Diseases (best score 7; 1 HIGH [TR-003 PWS], 3 STANDARD)

• TR-2026-05-05-019 · PMID 42081236 · 6/10 · Treatment Innovation (low confidence — plain-language summary only) ASO therapy amenability for infantile genetic epilepsies (JAMA Neurology, May 2026) — Gene-STEPS international consortium; systematic assessment of ASO therapy eligibility across genetically diagnosed infantile epilepsies. Flag for full-text retrieval.
• TR-2026-05-05-020 · PMID 42079593 · 5/10 · Diagnostics Inflammatory cytokines in Fabry disease vestibular/oculomotor dysfunction (Front Immunol, Apr 2026) — N=40 prospective; TNF-β associated with saccade latency (r=0.378, p=0.021); inflammatory biomarker panel in FD.
• TR-2026-05-05-021 · PMID 42078430 · 5/10 · Treatment Innovation POEM for Allgrove syndrome achalasia: long-term comparative cohort (Front Med, Apr 2026) — N=7, median 5.8yr follow-up at PUMCH; Eckardt 5.3→0.8; earlier onset (12.5 vs 33.8 years) vs idiopathic; treatment of choice evidence.

💡 UNSOLICITED FINDS

TR-2026-05-05-004 · PMID 42082916 · Score 8/10 · HIGH (see above) Saliva PCR for cCMV newborn screening — practice-changing diagnostic evidence for non-watchlist but high-signal finding.

TR-2026-05-05-023 · PMID 42079615 · Score 5/10 · STANDARD Ensemble ML for HIV immune reconstitution prediction (Front Immunol, Apr 2026) — N=5,436 real-world ART cohort; R²=0.768 for CD4+ without baseline CD4 — useful personalized monitoring tool in resource-variable settings.

📊 TODAY'S BREAKDOWN

By research category:

• Diagnostics: 8
• Treatment Innovation: 6
• Early Detection: 4
• Prevention: 4
• Genomics/Precision Medicine: 3
• Drug Development: 1
• Public Health: 2 (overlap)

By evidence maturity:

• Validated: 13
• Exploratory: 10
• Potentially Practice-Changing: 1 (TR-004 cCMV)

By watchlist topic:

*TR-001 (PMID 42082682) counted in both Hematologic malignancies and Novel therapeutics.

By source type: peer_reviewed 23 | preprint 0 Total raw search volume: ~1,900 records across all topics Deduplication: all 23 PMIDs confirmed new (>42071269, last emitted from 2026-05-04 run)

Topics with zero 8+ articles (this run): CBC/ML Hematology, Early Cancer Detection, Precision Oncology, Novel Therapeutics (standalone), Cardiovascular-Metabolic, Aging/Longevity

🔧 RUN NOTES

• Window expansion: NOT triggered (23 relevant records found, well above 5-article threshold).
• Truncation: All topics with >10 results hit the per-topic cap and were logged. AI/ML (413 results), Novel therapeutics (283), Sentinel (549) — top 10 reviewed; no high-signal articles known to be missed based on PMID recency ordering.
• CBC/ML hematology: 13th consecutive run with zero high-priority articles. Raw search (63 results) does not indicate topic scarcity but rather that day's results were not high enough signal. No expansion triggered.
• Aging/longevity: humans[MeSH] filter operational (148 results vs ~500+ without filter); 7-day rolling: consistently yielding STANDARD articles (5–7), no HIGH in recent 5 runs.
• Digepath (TR-002) note: Primary institution is Tsinghua Shenzhen/China + multi-center Chinese hospitals; no Western external validation yet — pipeline should note this for Phase 2 assessment.
• PMID 42081236 (ASO epilepsies, JAMA Neurology): Full abstract not retrieved — only plain language summary. Flagged for full-text retrieval in downstream phase. Score provisional (6/10, low confidence).
• Alerts sent: 4 of 4 HIGH articles sent to Telegram (within 5-article cap).